MNRI
MCID: MNN042
MIFTS: 62

Meningioma, Radiation-Induced (MNRI)

Categories: Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningioma, Radiation-Induced

MalaCards integrated aliases for Meningioma, Radiation-Induced:

Name: Meningioma, Radiation-Induced 56 13
Meningioma 58 36 29 54 6 71
Radiation Induced Meningioma 52 71
Mnri 56 52
Meningioma, Benign, No Icd-O Subtype 71

Characteristics:

Orphanet epidemiological data:

58
meningioma
Prevalence: 1-9/100000 (United States),1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare endocrine diseases


Summaries for Meningioma, Radiation-Induced

KEGG : 36 Meningiomas are the second-most common central nervous system tumor in adults. These tumors arise from arachnoid cells of the meninges, the covering layer of the brain. The majority of meningiomas tend to be benign, localized, and non-invasive. However, some meningiomas tend to be more aggressive with tendencies toward invasion of the surrounding brain, high propensity for recurrence, and in rare cases extracranial metastasis. Hereditary factors and ionizing radiation play an important role in the initiation of at least some meningiomas. Inactivation of the NF2 tumor suppressor gene is likely responsible for the initiation of more than half of all meningiomas and may cause a mesenchymal-like cytomorphology. Recently, novel mutations have been discovered in non-NF2 meningiomas. The somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas.

MalaCards based summary : Meningioma, Radiation-Induced, also known as meningioma, is related to optic nerve sheath meningioma and lung meningioma. An important gene associated with Meningioma, Radiation-Induced is NF2 (Neurofibromin 2), and among its related pathways/superpathways are MicroRNAs in cancer and Cytoskeletal Signaling. The drugs Thrombin and Fibrin Tissue Adhesive have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and bone, and related phenotypes are chromosomal breakage induced by ionizing radiation and increased sensitivity to ionizing radiation

More information from OMIM: 606190

Related Diseases for Meningioma, Radiation-Induced

Diseases related to Meningioma, Radiation-Induced via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1150)
# Related Disease Score Top Affiliating Genes
1 optic nerve sheath meningioma 34.6 SMARCB1 NF2
2 lung meningioma 34.3 PGR NF2
3 cerebral falx meningioma 34.3 SMARCB1 NF2
4 rhabdoid meningioma 34.3 VIM SMARCB1 NF2
5 anterior cranial fossa meningioma 34.2 SMARCB1 NF2
6 meningothelial meningioma 34.1 PGR NF2
7 skull base meningioma 34.0 PGR NF2
8 chordoid meningioma 33.9 VIM S100B MUC1
9 transitional meningioma 33.9 PGR NF2 MUC1 AP1B1
10 benign meningioma 33.8 PGR NF2 MKI67 EPB41L3
11 fibrous meningioma 33.8 VIM S100B NF2 MUC1
12 spinal canal and spinal cord meningioma 33.8 SMARCB1 PGR NF2
13 hemangiopericytoma, malignant 33.4 VIM S100B MUC1
14 schwannomatosis 1 33.1 SMARCB1 NF2
15 neurofibromatosis, type ii 33.0 RDX NF2 MSN EPB41L3
16 clear cell meningioma 32.8 VIM SUFU SMARCB1 S100B PGR NF2
17 monosomy 22 31.6 SMARCB1 NF2
18 spinal meningioma 31.5 SMARCB1 PGR NF2
19 secretory meningioma 31.4 VIM NF2 MUC1
20 acoustic neuroma 31.0 SMARCB1 RDX NF2 MSN
21 neurilemmomatosis 31.0 SUFU SMARCB1 NF2
22 benign ependymoma 30.9 VIM S100B NF2 MUC1
23 neuroma 30.9 SMARCB1 S100B NF2 MUC1
24 hemangioblastoma 30.9 VIM S100B MUC1
25 neurofibroma 30.9 VIM S100B NF2 MUC1
26 chordoma 30.9 VIM SMARCB1 S100B MUC1
27 cavernous hemangioma 30.7 VIM MUC1 MKI67
28 papilloma of choroid plexus 30.6 SMARCB1 S100B MUC1
29 rhabdoid tumor predisposition syndrome 1 30.6 VIM SMARCB1 MUC1
30 spindle cell sarcoma 30.6 VIM S100B NF2 MUC1
31 optic nerve glioma 30.5 VIM S100B NF2 MUC1
32 neurilemmoma 30.5 VIM SMARCB1 S100B RDX NF2 MUC1
33 non-functioning pituitary adenoma 30.5 S100B MUC1
34 medulloblastoma 30.5 VIM SUFU SMARCB1 S100B PDGFB H19
35 ganglioglioma 30.5 VIM SMARCB1 S100B
36 meningeal melanocytoma 30.4 S100B MUC1
37 clear cell ependymoma 30.3 VIM MUC1 EPB41L3
38 atypical teratoid rhabdoid tumor 30.3 VIM SMARCB1 S100B MUC1
39 perineurioma 30.3 VIM S100B MUC1
40 teratoma 30.3 VIM SMARCB1 H19
41 anaplastic ependymoma 30.2 VIM S100B NF2 MUC1
42 sarcoma 30.2 VIM SMARCB1 S100B PDGFB NF2 MUC1
43 neurofibromatosis, type iv, of riccardi 30.2 SMARCB1 RDX NF2 MSN
44 pleomorphic adenoma 30.2 VIM S100B MUC1
45 carcinosarcoma 30.2 VIM PGR MUC1
46 leiomyosarcoma 30.1 VIM S100B PGR MUC1
47 myxoid chondrosarcoma 30.1 SMARCB1 S100B MUC1
48 skull base cancer 30.0 PGR NF2
49 leiomyoma 30.0 VIM PGR MKI67
50 dermatofibrosarcoma protuberans 30.0 VIM S100B PDGFB

Graphical network of the top 20 diseases related to Meningioma, Radiation-Induced:



Diseases related to Meningioma, Radiation-Induced

Symptoms & Phenotypes for Meningioma, Radiation-Induced

Human phenotypes related to Meningioma, Radiation-Induced:

58 31 (show top 50) (show all 77)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chromosomal breakage induced by ionizing radiation 58 31 hallmark (90%) Very frequent (99-80%) HP:0010997
2 increased sensitivity to ionizing radiation 58 31 hallmark (90%) Very frequent (99-80%) HP:0011133
3 intracranial meningioma 58 31 hallmark (90%) Very frequent (99-80%) HP:0100009
4 nausea and vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002017
5 hypogonadotrophic hypogonadism 58 31 frequent (33%) Frequent (79-30%) HP:0000044
6 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
7 focal-onset seizure 58 31 frequent (33%) Frequent (79-30%) HP:0007359
8 secondary growth hormone deficiency 58 31 frequent (33%) Frequent (79-30%) HP:0008240
9 impotence 58 31 frequent (33%) Frequent (79-30%) HP:0000802
10 decreased circulating cortisol level 58 31 frequent (33%) Frequent (79-30%) HP:0008163
11 decreased serum estradiol 58 31 frequent (33%) Frequent (79-30%) HP:0008214
12 amenorrhea 58 31 frequent (33%) Frequent (79-30%) HP:0000141
13 pituitary hypothyroidism 58 31 frequent (33%) Frequent (79-30%) HP:0008245
14 decreased circulating acth level 58 31 frequent (33%) Frequent (79-30%) HP:0002920
15 bitemporal hemianopia 58 31 frequent (33%) Frequent (79-30%) HP:0030521
16 abnormal brain fdg positron emission tomography 58 31 frequent (33%) Frequent (79-30%) HP:0012658
17 focal t2 hypointense thalamic lesion 58 31 frequent (33%) Frequent (79-30%) HP:0012691
18 decreased circulating follicle stimulating hormone level 58 31 frequent (33%) Frequent (79-30%) HP:0030341
19 decreased circulating luteinizing hormone level 58 31 frequent (33%) Frequent (79-30%) HP:0030344
20 decreased serum testosterone level 31 frequent (33%) HP:0040171
21 increased circulating prolactin concentration 31 frequent (33%) HP:0000870
22 obesity 58 31 occasional (7.5%) Occasional (29-5%) HP:0001513
23 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
24 facial palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0010628
25 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
26 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
27 ophthalmoplegia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000602
28 papilledema 58 31 occasional (7.5%) Occasional (29-5%) HP:0001085
29 difficulty walking 58 31 occasional (7.5%) Occasional (29-5%) HP:0002355
30 slow decrease in visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0007924
31 abnormality of the sense of smell 58 31 occasional (7.5%) Occasional (29-5%) HP:0004408
32 abnormal cerebellum morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001317
33 upper limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003484
34 lower limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0007340
35 neurofibromas 58 31 occasional (7.5%) Occasional (29-5%) HP:0001067
36 hemiparesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001269
37 abnormal kinetic perimetry test 58 31 occasional (7.5%) Occasional (29-5%) HP:0030591
38 oculomotor nerve palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0012246
39 weak extraocular muscles 58 31 occasional (7.5%) Occasional (29-5%) HP:0007715
40 hypothalamic hypothyroidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0008237
41 abnormality of central sensory function 58 31 occasional (7.5%) Occasional (29-5%) HP:0011730
42 neoplasm of the anterior pituitary 58 31 occasional (7.5%) Occasional (29-5%) HP:0011750
43 enlarged pituitary gland 58 31 occasional (7.5%) Occasional (29-5%) HP:0012505
44 visual acuity test abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0030532
45 spinal meningioma 58 31 occasional (7.5%) Occasional (29-5%) HP:0100010
46 trigeminal neuralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100661
47 reduced circulating prolactin concentration 31 occasional (7.5%) HP:0008202
48 neurological speech impairment 58 31 very rare (1%) Very rare (<4-1%) HP:0002167
49 emotional lability 58 31 very rare (1%) Very rare (<4-1%) HP:0000712
50 blindness 58 31 very rare (1%) Very rare (<4-1%) HP:0000618

Clinical features from OMIM:

606190

GenomeRNAi Phenotypes related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Meningioma, Radiation-Induced:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.5 EPB41L3 MN1 NF2 NOS2 PGR SMARCB1
2 respiratory system MP:0005388 9.28 AP1B1 MN1 MSN NF2 NOS2 OGA

Drugs & Therapeutics for Meningioma, Radiation-Induced

Drugs for Meningioma, Radiation-Induced (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 251)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2 Fibrin Tissue Adhesive Phase 4
3 Hemostatics Phase 4
4 Coagulants Phase 4
5
Tranexamic Acid Approved Phase 3 1197-18-8 5526
6
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
7
Donepezil Approved Phase 3 120014-06-4 3152
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Cisatracurium Approved Phase 3 96946-41-7
13
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
14
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
15
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
18
Histamine Approved, Investigational Phase 3 51-45-6 774
19
Cyproheptadine Approved Phase 3 129-03-3 2913
20
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Antifibrinolytic Agents Phase 3
23 Progestins Phase 3
24 Nootropic Agents Phase 3
25 Cholinergic Agents Phase 3
26 Cholinesterase Inhibitors Phase 3
27 Liver Extracts Phase 3
28 Cola Phase 3
29 Emetics Phase 3
30 Narcotics Phase 3
31 Anesthetics, General Phase 3
32 Analgesics, Opioid Phase 3
33 Adjuvants, Anesthesia Phase 3
34 Anesthetics, Intravenous Phase 3
35 Antihypertensive Agents Phase 3
36 Analgesics Phase 3
37 Tocolytic Agents Phase 3
38 Anti-Arrhythmia Agents Phase 3
39 Vasoconstrictor Agents Phase 3
40 Anesthetics Phase 3
41 Anticonvulsants Phase 3
42 Central Nervous System Depressants Phase 3
43 Calcium, Dietary Phase 3
44 calcium channel blockers Phase 3
45 Gastrointestinal Agents Phase 3
46 Central Nervous System Stimulants Phase 3
47 Neurotransmitter Agents Phase 3
48 Dermatologic Agents Phase 3
49 Dopamine Uptake Inhibitors Phase 3
50 Dexmethylphenidate Hydrochloride Phase 3

Interventional clinical trials:

(show top 50) (show all 202)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
5 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
6 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
7 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
9 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
17 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Unknown status NCT00895622 Phase 2
18 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
19 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
20 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Unknown status NCT01117844 Phase 1, Phase 2
21 Proton Radiation for Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
22 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
23 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
24 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
25 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
26 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Completed NCT00626730 Phase 2
27 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
28 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
29 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
30 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
31 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
32 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
33 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
34 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
35 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
36 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
37 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
38 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
39 A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas Completed NCT00004868 Phase 1, Phase 2 semaxanib
40 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
41 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
42 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
43 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
44 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
45 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
46 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
47 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 3 mg/kg;Nivolumab - 480 mg;Nivolumab - 1 mg/kg
48 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
49 A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation Recruiting NCT03071874 Phase 2 AZD2014
50 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Recruiting NCT01849484 Phase 2

Search NIH Clinical Center for Meningioma, Radiation-Induced

Genetic Tests for Meningioma, Radiation-Induced

Genetic tests related to Meningioma, Radiation-Induced:

# Genetic test Affiliating Genes
1 Meningioma 29

Anatomical Context for Meningioma, Radiation-Induced

MalaCards organs/tissues related to Meningioma, Radiation-Induced:

40
Brain, Pituitary, Bone, Spinal Cord, Breast, Lung, Thyroid

Publications for Meningioma, Radiation-Induced

Articles related to Meningioma, Radiation-Induced:

(show top 50) (show all 14209)
# Title Authors PMID Year
1
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. 54 61 6
8162072 1994
2
Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas. 54 61 6
2212004 1990
3
A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 61 6
12085208 2002
4
Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. 61 6
7868131 1995
5
Chromosome translocation t(14;22) and oncogene (c-sis) variant in a pedigree with familial meningioma. 61 6
3969118 1985
6
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. 61 46
19703993 2009
7
Cytogenetic study of six cases of radiation-induced meningiomas. 56
11376799 2001
8
A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. 6
3133569 1988
9
Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. 54 61
19922547 2010
10
Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. 54 61
19747051 2010
11
Expression of podoplanin and calretinin in meningioma: an immunohistochemical study. 54 61
20425044 2010
12
Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies. 54 61
20235875 2010
13
Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. 54 61
20054806 2010
14
Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. 54 61
19703265 2010
15
Genomic deletions at 1p and 14q are associated with an abnormal cDNA microarray gene expression pattern in meningiomas but not in schwannomas. 54 61
19963129 2010
16
Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. 54 61
19885562 2009
17
Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. 54 61
19429976 2009
18
Diffuse craniospinal metastases of intraventricular rhabdoid papillary meningioma with glial fibrillary acidic protein expression: a case report. 54 61
19482417 2009
19
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. 54 61
19451225 2009
20
Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation. 54 61
19194275 2009
21
[Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. 54 61
19603293 2009
22
Meningioma in untreated congenital adrenal hyperplasia: a relationship? 54 61
19039522 2009
23
Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. 54 61
19521276 2009
24
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. 54 61
18953429 2008
25
Paraneoplastic acanthosis nigricans and silent meningioma producing transforming growth factor-alpha. 54 61
19049942 2008
26
Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. 54 61
18778186 2008
27
MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression. 54 61
18632758 2008
28
Cyclin D1 immunoreactivity in meningiomas. 54 61
18379871 2008
29
Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. 54 61
18808065 2008
30
Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. 54 61
18418552 2008
31
BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. 54 61
18474292 2008
32
Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. 54 61
17707480 2008
33
Multiple intracranial meningiomas causing papilledema and visual loss in a patient with nevoid Basal cell carcinoma syndrome. 54 61
18347458 2008
34
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. 54 61
17962031 2008
35
Specific genes expressed in association with progesterone receptors in meningioma. 54 61
18172325 2008
36
Periosteal osteoblastoma of the calvaria mimicking a meningioma. 54 61
18359169 2008
37
Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. 54 61
17924978 2008
38
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. 54 61
17912429 2007
39
Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. 54 61
17785665 2007
40
Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study. 54 61
17721284 2007
41
Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. 54 61
17695396 2007
42
Molecular genetics of meningiomas: from basic research to potential clinical applications. 54 61
17460514 2007
43
Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. 54 61
17415213 2007
44
The astrocytic response towards invasive meningiomas. 54 61
17359357 2007
45
Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. 54 61
17225937 2007
46
Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. 54 61
17181554 2007
47
NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. 54 61
17319281 2007
48
New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. 54 61
17284108 2007
49
Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? 54 61
17961045 2007
50
Histological classification and molecular genetics of meningiomas. 54 61
17110285 2006

Variations for Meningioma, Radiation-Induced

ClinVar genetic disease variations for Meningioma, Radiation-Induced:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NF2 NM_016418.5(NF2):c.995del (p.Lys332fs)deletion Pathogenic 3284 rs587776563 22:30064429-30064429 22:29668440-29668440
2 NF2 NM_016418.5(NF2):c.169C>T (p.Arg57Ter)SNV Pathogenic 3285 rs121434259 22:30032794-30032794 22:29636805-29636805
3 PDGFB PDGFB, 135-BP DEL, IVS5deletion Pathogenic 12598
4 t(5;22)(q31.2;q12.1)Translocation Likely pathogenic 635000 22:28192751--1
5 DNMT1 NM_001130823.3(DNMT1):c.1645-1G>TSNV Likely pathogenic 635178 rs1568234664 19:10265450-10265450 19:10154774-10154774
6 PTEN NM_000314.7(PTEN):c.701G>A (p.Arg234Gln)SNV Uncertain significance 7840 rs121909235 10:89717676-89717676 10:87957919-87957919

Copy number variations for Meningioma, Radiation-Induced from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 81307 14 101400000 103200000 Loss Meningioma
2 109410 17 25800000 38100000 Copy number HER-2 Meningioma
3 116388 17 6500000 10700000 Copy number TP53 Meningioma

Expression for Meningioma, Radiation-Induced

Search GEO for disease gene expression data for Meningioma, Radiation-Induced.

Pathways for Meningioma, Radiation-Induced

Pathways related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.95 VIM RDX PDGFB MIR200A
2 11.51 VIM RDX NF2 MUC1 MSN
3 11.49 VIM NOS2 MUC1
4 11.03 VIM S100B PDGFB

GO Terms for Meningioma, Radiation-Induced

Cellular components related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ruffle GO:0001726 9.33 S100B RDX NF2
2 apical part of cell GO:0045177 9.13 RDX NF2 MSN
3 filopodium GO:0030175 8.8 RDX NF2 MSN

Biological processes related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 establishment of endothelial barrier GO:0061028 9.43 RDX MSN
2 positive regulation of cellular protein catabolic process GO:1903364 9.4 RDX MSN
3 positive regulation of early endosome to late endosome transport GO:2000643 9.37 RDX MSN
4 positive regulation of protein localization to early endosome GO:1902966 9.32 RDX MSN
5 paracrine signaling GO:0038001 9.26 PGR PDGFB
6 regulation of cell shape GO:0008360 9.26 S100B RDX MSN EPB41L3
7 positive regulation of histone H4 acetylation GO:0090240 9.16 SMARCB1 MUC1
8 regulation of organelle assembly GO:1902115 8.62 RDX MSN

Molecular functions related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 9.13 VIM MSN EPB41L3
2 cytoskeletal protein binding GO:0008092 8.92 RDX NF2 MSN EPB41L3

Sources for Meningioma, Radiation-Induced

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....